The CNS Market Outlook to 2012 is a New Report That Provides a Detailed Epidemiological Analysis of Major Indications Within the CNS Disorders Market

   CNS disorders constitute one of the most significant components of healthcare spending in the developed world, contributing to an estimated 35% of the disease burden within the seven major pharma markets. However, an increased presence of generic products and lack of innovative product launches have prompted a slowdown in market growth, which pharma and biotech companies are addressing through a shift in R&D focus towards disease areas with relatively low levels of innovation, such as Alzheimer's and Parkinson's disease.

   The CNS Market Outlook to 2012' is a new report that provides a detailed epidemiological analysis of major indications within the CNS disorders market, and examines the factors impacting their prevalence. The current opportunities and threats facing the market are assessed and the most promising potential growth areas across all indications are highlighted. The report also profiles the key trends influencing treatment sales and analyses the competitive dynamics of leading brands within each indication. Discover the key trends and growth drivers within the CNS market, assess the competitive dynamics of leading pharma companies and evaluate the future prospects of major products with this new report...

   Some Key Findings From This Report...

   -Alzheimer's disease is forecast to be the primary driver of growth within the CNS market over the 2006-12 period, with a CAGR of 13.1%. Factors driving this growth include new product launches and the implementation of strategies to protect revenue streams.

   -The leading nine companies' CNS portfolios recorded a growth rate of 7.0% in 2005-6, representing sales of $57.9m. However, sales have become increasingly volatile due to recent patent expiries.

   -Five of the most promising compounds identified by this report are replacements for blockbusters that are forecast to lose patent protection by 2012. These include J&J's Invega (paliperidone), Wyeth's DVS-233 and Merck's potential anti-depressant Vilazodone.

   -Pfizer continues to face substantial revenue losses as a result of significant generic competition, however sales of Lyrica are forecast to reinforce the company's portfolio growth over the 2006-12 period.

   -Heavy genericization will cause epilepsy to become a fiercely contested market. Major companies have begun to explore new strategies and indications in an effort to protect sales revenues.

   Key Issues Examined In This Report...

   -Increasing patient population. Physicians and patients are becoming increasingly aware of CNS disorders as the numbers of those afflicted by such conditions continues to rise. This is helping to gradually erode the social stigma attached to the diseases.

   -Lifecycle extension/Generics strategies. Imminent patent expiries for major brands have resulted in companies investigating new indications and re-formulation strategies to extend patent validity and safeguard revenue streams. Companies have also begun to

   manufacture and market generic versions of their products, a notable example of which is Pfizer's launch of Gabapentin to replace Neurontin

   -Alzheimer's market potential. Therapies indicated for the treatment of AD feature the strongest growth prospects, due to a high level of unmet need, moderate genericization and new drug classes.

   -CNS franchise challenges. Franchise sales across major therapy areas continue to be threatened by negative events associated with SSRI's. Recent withdrawals of pergolide-based products and unscheduled releases of negative clinical data have also jeopardized sales potential.

   Keywords: Alzheimer Disease, Central Nervous System Disease, Central Nervous System Infection, Central Nervous System Tumors, Epidemiology, Neurology, Neurosurgery, Pharmaceuticals, Research and Markets.

   This article was prepared by Pain & Central Nervous System Week editors from staff and other reports. Copyright 2007, Pain & Central Nervous System Week via NewsRx.com.

Return to Medical Patents Alert Section